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individual CEF peptides were recognized in an unpredicted 
fashion in 57 test cases. Moreover, the frequency of CD8 
cells responding to a single peptide did not reflect on the 
number of CD8 cells targeting other determinants on the 
same antigen. Thus, reliance on one or a few predicted pep-
tides provides a rather inaccurate assessment of antigen-
specific CD8 cell immunity, strongly arguing for the use of 
peptide pools for immune monitoring.
Keywords Immune monitoring · Predicted antigenic 
peptides · Peptide pools · Tetramers, dextramers, 
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Abbreviations
APC  Antigen-presenting cells
CD  Cluster of differentiation
CEF  Cytomegalo-, Epstein–barr-, Influenza virus
CMV  Cytomegalovirus
EBV  Epstein–barr virus
ELISPOT  Enzyme-linked immunospot assay
HLA  Human leukocyte antigen
ICS  Intracellular cytokine staining
MHC  Major histocompatibility complex
PBMC  Peripheral blood mononuclear cells
SFU  Spot-forming unit
TCR  T cell receptors
Introduction
CD8 cells recognize 9- to 10-amino-acid-long peptide frag-
ments of protein antigens, including tumor antigens. Such 
antigenic peptides are displayed to the T cell receptors 
(TCR) of CD8 cells on MHC Class I molecules of antigen-
presenting cells (APC). The antigenic peptides are bound in 
Abstract Detection of antigen-specific CD8 cells fre-
quently relies on the use of peptides that are predicted to 
bind to HLA Class I molecules or have been shown to 
induce immune responses. There is extensive knowledge 
on individual HLA alleles’ peptide-binding requirements, 
and immunogenic peptides for many antigens have been 
defined. The 32 individual peptides that comprise the CEF 
peptide pool represent such well-defined peptide deter-
minants for Cytomegalo-, Epstein–barr-, and Influenza 
virus. We tested the accuracy of these peptide recognition 
predictions on 42 healthy human donors that have been 
high-resolution HLA-typed. According to the predictions, 
241 recall responses should have been detected in these 
donors. Actual testing showed that 36 (15 %) of the pre-
dicted CD8 cell responses occurred in the high frequency 
range, 41 (17 %) in mid-frequencies, and 45 (19 %) were at 
the detection limit. In 119 instances (49 %), the predicted 
peptides were not targeted by CD8 cells detectably. The 
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a dedicated peptide-binding groove of the Class I molecule 
with certain amino acids of the peptide chain attaching to 
the Class I molecule (MHC contact residues) while other 
residues are facing the TCR (TCR contact residues) [1]. 
There are over 100 MHC/HLA Class I alleles in the human 
population distributed over three loci of the human leuko-
cyte antigen gene complex (HLA)) Of this sizable library 
of alleles, each human subject expresses up to six different 
HLA Class 1 molecules, constituting his/her unique HLA 
type [2].
Each allelic HLA molecule variant has a unique peptide-
binding specificity dictated by differences in the amino 
acid sequence within the peptide-binding groove [3]. The 
expression of a certain HLA allele in any given individual 
will therefore predetermine what peptide segment(s) of an 
antigen can be presented to CD8 cells in that individual. 
CD8 cells in individuals with shared HLA Class I alleles 
can respond to the same peptide of a given protein anti-
gen, but CD8 cells in individuals expressing different HLA 
alleles will respond to different peptides. Peptide recogni-
tion by CD8 cells is therefore highly variable among indi-
viduals of an outbred population, as variable as the HLA 
system itself, the latter primarily dictating the former. This 
becomes particularly important for understanding the vari-
ability of the anti-tumor T cell response in different indi-
viduals. It is thought that HLA polymorphism and polygen-
ism and the resulting individualized peptide recognition 
have evolved to protect the species from mistakes of self-/
non-self-discrimination by T cells ensuring that complica-
tions of infections or autoimmune diseases would affect 
only individuals with certain HLA alleles, but not endanger 
the entire population [4].
Table 1  List of CEF peptides 
and their restricting MHC Class 
I alleles as originally defined
CEF # Virus Antigen source Epitope sequence HLA Restric-
tion
CEF-01 Influenza PB1 (591–599) VSDGGPNLY A1
CEF-02 Influenza NP(44–52) CTELKLSDY A1
CEF-03 Influenza M1 (58–66) GILGFVFTL A2
CEF-04 Influenza PA (46–54) FMYSDFHFI A2
CEF-05 EBV LMP2A (426–434) CLGGLLTMV A2
CEF-06 EBV BMLF1 (259–267) GLCTLVAML A2
CEF-07 HCMV pp65 (495–503) NLVPMVATV A2
CEF-08 Influenza NP (91–99) KTGGPIYKR Aw68
CEF-09 Influenza NP (342–351) RVLSFIKGTK A3
CEF-10 Influenza NP(265–273) ILRGSVAHK A3
CEF-11 EBV BRLF1 (148–156) RVRAYTYSK A3
CEF-12 EBV EBNA 3a (603–611) RLRAEAQVK A3
CEF-13 Influenza M1 (13–21) SIIPSGPLK A11
CEF-14 EBV EBNA 3b (399–408) AVFDRKSDAK A11
CEF-15 EBV EBNA 3b (416–424) IVTDFSVIK A11
CEF-16 EBV BRLF1 (134–143) ATIGTAMYK A11
CEF-17 EBV BRLF1 (28–37) DYCNVLNKEF A24
CEF-18 Influenza NP (418–426) LPFDKTTVM B7
CEF-19 EBV EBNA 3a (379–387) RPPIFIRRL B7
CEF-20 Influenza NP (380–388) ELRSRYWAI B8
CEF-21 EBV BZLF1 (190–197) RAKFKQLL B8
CEF-22 EBV EBNA 3a (325–333) FLRGRAYGL B8
CEF-23 EBV EBNA 3a (158–166) QAKWRLQTL B8
CEF-24 HCMV pp65 (378–389) SDEEEAIVAYTL B18
CEF-25 Influenza NP (383–391) SRYWAIRTR B27
CEF-26 Influenza M1 (128–135) ASCMGLIY B27
CEF-27 EBV EBNA 3c (258–266) RRIYDLIEL B27
CEF-28 EBV EBNA 3a (458–466) YPLHEQHGM B35
CEF-29 HCMV pp65 (123–131) IPSINVHHY B35
CEF-30 EBV EBNA 3c (281–290) EENLLDFVRF B44
CEF-31 HCMV pp65 (511–525) EFFWDANDIY B44
CEF-32 HCMV pp65 (417–426) TPRVTGGGAM B7
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Since allelic HLA molecules dictate what peptides can 
be recognized by CD8 cells, considerable effort has been 
invested in the past two decades in understanding the rules 
of HLA-peptide binding. Peptide-binding motifs have been 
identified for most Class I alleles that permit us to predict 
peptide sequences of the antigen that are likely to bind to a 
given allele with high accuracy, and thus predict peptides 
that are potential antigenic determinants for CD8 cell rec-
ognition in individuals expressing that HLA allele [5–7]. 
The precision of these models has been extensively verified 
in vitro by HLA-peptide-binding studies.
Therefore, presently, we have a comprehensive knowl-
edge base about peptides of antigens that can bind to the 
different HLA allelic molecules, and therefore we can iden-
tify peptides that can be presented on APC to CD8 cells in 
the context of an individual’s unique HLA type. However, 
the downstream consequences of antigen presentation are 
less known. From the many peptides predicted to bind to 
HLA molecules expressed in a host, often only few are 
actually recognized by CD8 cells. In a systematic study by 
Anthony et al., the CD8 cell response to the Core protein of 
Hepatitis C virus (a small antigen of 192 amino acids long) 
was studied [8]. Peptide prediction algorithms suggested 
that 43 nonamer peptides could bind to the HLA Class I 
alleles expressed in an individual. However, only two adja-
cent peptides (constituting a single determinant) were actu-
ally recognized by CD8 cells when all possible nonamers 
of 183 individual peptides that walked the sequence of the 
core antigen in steps of single amino acids were tested.
Presently it is unknown why CD8 cell recognition tar-
gets only few of the peptides on an antigen that can bind to 
HLA molecules expressed in a given individual. For many 
antigens, such immune dominant peptides—also called 
determinants—have been defined empirically, by studying 
the CD8 cell response itself. The 32 individual peptides 
that comprise the CEF peptide pool, that is widely used as 
a positive control for CD8 cell testing, represent such well-
defined peptide determinants for Cytomegalo-, Epstein–
barr, and Flu virus (Table 1) [9]. Each of these peptides 
has been verified to be recognized by CD8 cells, and the 
respective HLA allele used for antigen presentation has 
been defined (see references in [9]).
Presently, the predictability of peptide determinant rec-
ognition by CD8 cells in individuals who share certain 
HLA alleles is largely unknown. Each CEF peptide, for 
example, is a bona fide CD8 cell determinant in individu-
als that express the corresponding HLA allele, but do CD8 
cells in all individuals who share that HLA allele uniformly 
recognize that peptide, and if so, do they do it in an immune 
dominant fashion?
It is well established that even individual mice within a 
given mouse strain, in which all mice express identical H-
2 alleles (the H-2 gene system is the murine equivalent of 
the human MHC system), can give rise to individual peptide 
recognition patterns [10, 11]. For example, if a mouse strain 
can mount a T cell response to peptide determinants “A”, 
“B”, “C”, and “D” of an antigen, all mice within the strain 
will respond to each of these peptides if the mice are immu-
nized with peptides “A”, “B”, “C” or, “D”. After immuniza-
tion with the antigen itself, however, some mice within the 
strain will mount a T cell response only to determinant “A”, 
other mice will respond to “B”, yet others will target “C” 
or “D”. In these murine models, determinant recognition is 
predictable in the sense that only peptides “A”, “B”, “C” or, 
“D” will be recognized, but determining which of the pep-
tides will be recognized by any given individual mouse was 
found to be so random that the term “aleatory determinant 
recognition” was coined [10, 11] (Alea means dice in Latin). 
How predictable is, therefore, the recognition of bona fide 
determinants in humans? This question is central to immune 
monitoring, when peptides (and if using the tetramer/pen-
tamer/dextramer or other multimer approach also MHC/
HLA alleles) need to be chosen for measuring the frequen-
cies and effector classes of in vivo induced CD8 cells.
In this study we tested on 42 healthy human donors who 
have been subjected to high-resolution HLA-typing in order 
to determine the accuracy of the CEF peptide recognition 
predictions. We studied whether all HLA-A*0201-positive 
donors who have been infected with Cytomegalo-, Epstein–
barr-, and Flu virus show a CD8 cell response to the pre-
defined HLA-A*0201-restricted peptides of these viruses. 
And, if the donor responded, we distinguished whether the 
response is dominant, one of several weaker (subdomi-
nant) responses, a barely detectable (cryptic) response, or 
whether the predicted peptide was not recognized at all, 
while responses to other peptides of the virus prevailed. We 
also established the number of times unpredicted peptides 
of the virus were recognized in a dominant fashion. There-
fore, to the practical end, we asked, whether reliance on 
select “immunodominant” peptides is a reliable alternative 
to agnostic immune monitoring with peptide pools.
Materials and methods
Human subjects and peripheral blood mononuclear 
cells (PBMC)
Forty-two HLA-A*0201-positive healthy human donors 
were selected from CTL’s ePBMC library. All donors were 
high-resolution HLA-typed for A, B, and C alleles, and were 
seropositive for Cytomegalovirus (CMV), Epstein–barr virus 
(EBV), and Influenza virus. The subjects tested in this study 
were healthy adults aged 22–45. These PBMC donors were 
recruited by HemaCare (Van Nyus, Ca), and the PBMC were 
isolated by leucapheresis at HemaCare using HemaCare 
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IRBs. The PBMC were cryopreserved at CTL (Cleveland, 
OH) and stored in vapor liquid nitrogen until testing in an 
Enzyme-linked immunospot (ELISPOT) assay. Thawing, 
washing, and counting of the cryopreserved cells were done 
as previously described [12]. Within maximally 2 h after 
thawing, the cells were transferred into the ELISPOT test sys-
tem. In select experiments, CD4 + or CD8 + T cell subsets 
were depleted from PBMC using a magnetic bead selection 
kit (Stem Cell Technologies, Canada). The depletion assay 
was performed according to manufacturer’s instructions.
Antigens
The individual CEF peptides, with amino acid sequences spec-
ified in Table 1, were purchased from Panatecs (Heilbronn, 
Germany) and were of more than 95 % purity. The peptides 
were dissolved in CTL-Test Medium (CTLT-005 –by CTL, 
Shaker Hts., OH, USA) and added to the ELISPOT test sys-
tem at a final concentration of 1 µg/mL. HCMVpp consists of 
a pool of 138 15-mer peptides that cover the sequence of the 
HCMVpp65 protein—this peptide pool, Pepmix HCMVpp65, 
was purchased from JPT Peptides (Berlin, Germany).
Human interferon‑γ ELISPOT assay
The human interferon-γ (IFN-γ) ELISPOT assay was per-
formed as we previously described [13]. Briefly, the PVDF 
membrane was coated with capture antibody overnight. Pep-
tide antigens were plated first in a volume of 100 μL per well at 
2× the final concentrations. The plates containing the antigen 
were stored at 37 °C in a humidified CO2 incubator until the 
PBMC were ready for plating. The thawed PBMC were added 
at 4 × 105/cells per well in 100 μL using wide-bore pipette 
tips. Plates were gently tapped on each side to ensure even dis-
tribution of the cells as they settled and incubated for 24 h at 
37 °C in a humidified CO2 incubator. Following completion of 
the ELISPOT detection, the plates were air-dried in a laminar 
flow hood prior to analysis. The ELISPOT plates were scanned 
and analyzed using an ImmunoSpot® S5 Ultimate Reader 
from CTL. The number of spots (spot-forming units, SFU) 
was automatically calculated by the ImmunoSpot® Software 
(CTL, Shaker Hts., OH) for each antigen stimulation condition 
versus the medium (negative) control using the SmartCount™ 
and Autogate™ functions [14, 15]. In all experiments and for 
all donors, the negative control wells had less than 10 SFU per 
well. Spot counts reported for the respective antigen-stimulated 
test conditions are means and standard deviation from triplicate 
wells, without the medium control subtracted.
Statistical analysis
Mean and standard deviation from triplicate wells were cal-
culated. Student’s t test was used to determine significance. 
Test results were defined as negative if the p value did not 
reach 0.05.
Results and discussion
Dominant, subdominant, and cryptic CD8 cell 
responses
PBMC of 42 HLA-A*0201-positive healthy human donors 
were tested in an IFN-γ ELISPOT assay for reactivity 
for each of the 32 individual CEF peptides. Operating at 
single-cell resolution, as performed, the IFN-γ ELIS-
POT assay establishes the number of peptide-triggered 
Fig. 1  Example of immune dominance for two predicted peptides, 
and lack of response to six other predicted peptides (Donor # 12). The 
HLA type of this donor is shown in the insert. The data are described 
in the Text. Predicted responses are in blue and predicted responses to 
which this donor did not respond are highlighted by arrows
Fig. 2  Example of immune dominance for an unpredicted pep-
tide with magnitude of response higher than predicted dominant 
responses, while four predicted peptides are not recognized (Donor 
#28). The HLA type of this donor is specified in the insert. The 
results for this donor are described in the Text. Predicted responses 
are in blue, unpredicted responses in green. Predicted responses that 
scored negative are highlighted by arrows
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IFN-γ-producing cells within the 400,000 PBMC plated 
per well [16]. CEF peptide-induced IFN-γ production has 
been established by others [9] and by us [17] as CD8 cell-
derived. Therefore, this assay establishes the frequency of 
peptide-reactive CD8 cells within the PBMC, providing a 
measure for the clonal size of peptide-reactive CD8 cells 
in a given PBMC donor, that is, the magnitude of CD8 cell 
immunity that targets a particular peptide.
The magnitudes of recall responses detected were 
divided into three categories. The “immune dominant” 
category was assigned to responses exceeding 100 spots 
per well (with 400,000 PBMC plated per well, this cor-
responds to a frequency of >0.04 %). One hundred spots 
per well represents a very strong and clear-cut response in 
ELISPOT as the background in these assays was for each 
PBMC donor less than 10 spots per well, and in many 
cases zero spots per well (all data not shown—examples 
are provided in Fig. 6b). The 0.04 % cutoff for this cate-
gory is relevant with regard to data comparisons using flow 
cytometry-based frequency measurements of peptide-stim-
ulated CD8 cells by staining for intracellular IFN-γ as the 
detection limit of Intracellular cytokine staining (ICS) is in 
this range, around 0.01 % [18]. Responses that were estab-
lished as dominant by the more sensitive ELISPOT assay, 
therefore, can be expected to be detectable by ICS, albeit at 
the detection limit of ICS.
The detection limit for ELISPOT as performed, plat-
ing 400,000 PBMC/well, is one IFN-γ-producing cell in 
400,000 cells. As ELISPOT counts among replicate wells 
follow a normal distribution the Student’s t test is suited to 
identify positive responses [19]. All peptides were tested 
in triplicate wells, and the spot counts were compared to 
the medium control, also measured in triplicate wells. Test 
results were defined as negative if the p value did not reach 
0.05. Test results that reached this cutoff for significance 
but were less than 30 spots per well were defined as weakly 
positive, i.e., cryptic. Test results in between cryptic and 
dominant were called subdominant.
CEF peptide recall responses for individual donors
Four donors with typical response patterns are shown in 
Figs. 1, 2, 3, and 4. Responses of Donor 12 are shown in 
Fig. 1. This donor responded to four of ten predicted pep-
tides. Based on the HLA type of this donor (shown in the 
insert of Fig. 1), one would expect responses to CEF-3 
and CEF-4 (A2-restricted flu peptides), CEF-5 and CEF-6 
(A2-restricted EBV peptides), CEF-7 (A2-restricted CMV 
peptide), CEF-9 and CEF-10 (A3-restricted flu peptides), 
CEF-11 and CEF-12 (A3-restricted EBV peptides), and 
CEF-24 (a B18-restricted CMV peptide). This donor 
responded in a dominant fashion to two of the predicted 
peptides, CEF-7 and CEF-11, subdominant to CEF-3, cryp-
tic to CEF-10, but did not respond to the six other predicted 
peptides (highlighted by the arrows). There was no unpre-
dicted response in this donor.
Figure 2 shows the test results for Donor 28. This donor 
provides an example for immune dominance of an unpre-
dicted peptide with magnitude of response higher than pre-
dicted dominant responses, while four predicted peptides 
were found to be negative. Based on the HLA type of this 
donor, one would expect to detect responses to 11 peptides: 
CEF-3 and CEF-4 (A2-restricted flu peptides), CEF-5 and 
CEF-6 (A2-restricted EBV peptides), CEF-7 (A2-restricted 
CMV peptide), CEF-9 and CEF-10 (A3-restricted flu pep-
tides), CEF-11 and CEF-12 (A3-restricted EBV peptides), 
CEF-30 (B44-restricted EBV peptide), and CEF-31 (B44-
restricted CMV peptide). Of these, two peptides were rec-
ognized in a dominant fashion (CEF-3 and CEF-7), two 
were subdominant (CEF-10 and CEF-30), and responses to 
the other three were cryptic (CEF-5, CEF-6, and CEF-11). 
The dominant response was to an unpredicted peptide, CEF 
Fig. 3  Immunodominant, subdominant and cryptic responses with 
both predicted and non-predicted peptides (Donor #17). Legend to 
Fig. 2 applies
Fig. 4  Only one donor out of the 42 tested responded to all predicted 
peptides, but also in a codominant fashion to an unpredicted one. 
Legend to Fig. 2 applies
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24, originally described as an HLA-B18-restricted CMV 
peptide, but this donor is B18 negative. CEF-24 apparently 
can also bind to one of the Class I alleles expressed by this 
donor. Four predicted peptides were not recognized: CEF- 
4, CEF-9, CEF-12, and CEF-31 (highlighted by arrows).
Donor 17 (Fig. 3) provides an example of a CD8 cell 
response pattern in which immunodominant, subdomi-
nant, and cryptic responses encompass both predicted 
and non-predicted peptides. In this donor, predicted 
responses to seven peptides can be expected: CEF-3 and 
CEF-4 (A2-restricted flu peptides), CEF-5 and CEF-6 
(A2-restricted EBV peptides), CEF-7 (A2-restricted 
CMV peptide), CEF-30 (B44-restricted EBV peptide), 
and CEF-31 (B44-restricted CMV peptide). This donor 
responded to five of the seven predicted peptides. A 
dominant response was seen to CEF-3 and CEF-7, a sub-
dominant response to CEF-6, and cryptic responses to 
CEF-5 and CEF-30. This donor produced five unpredicted 
responses: dominant responses to CEF-11, CEF-15, and 
CEF-19, and subdominant responses to CEF-23 and CEF-
27. Two predicted peptides were not recognized: CEF- 4 
and CEF-31 (highlighted by arrows).
Figure 4 shows the recall response for Donor 4. This 
donor was the only one of the 42 tested who responded 
to all predicted peptides, but also in a codominant fashion 
to an unpredicted one. This HLA-A2 homozygotic donor 
Fig. 5  Predicted versus actually detected responses for all donors. 
Forty-two donors were tested for the 32 individual CEF peptides. 
a Of the predicted 241 recall responses, in 122 instances recall 
responses of various magnitudes were detected, graded as dominant, 
subdominant, and cryptic, as specified in the Text. In 119 instances 
no response was detected. b Predicted versus unpredicted responses 
among positives. Fifty-seven unpredicted responses (shown in green) 
were seen versus the 122 predicted responses. Within the unpredicted 
responses 20 (35 %) were dominant, 20 (35 %) were subdominant, 
and 17 (30 %) were cryptic
Fig. 6  Individual donors who do not respond to an allegedly immune 
dominant peptide of HCMV, CEF-7, can vigorously target other 
determinants of the virus. a HCMVpp triggers IFN-γ production pri-
marily by CD8 cells. Unseparated whole PBMC, and CD4- or CD8-
cell-depleted PBMC were tested, as specified. The mean and SD of 
test results obtained in triplicate wells are shown. b Test results for 
HLA A2-0201-restricted CEF-7 peptide versus the HCMVpp peptide 
pool. CEF7 negative donors are highlighted
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responded to all five predicted A2-restricted peptides, 
mounting codominant responses to CEF-4, CEF-5, and 
CEF-7, a subdominant response to CEF-3, and a cryptic 
response to CEF-6. While being HLA-B27 negative, this 
donor showed an unpredicted codominant response to CEF-
26 that was originally described as an HLA-B27-restricted 
peptide. This unpredicted response was of the same order 
of magnitude as three predicted responses, and more than 
10 times stronger than the predicted responses to CEF-3 
and CEF-6. Unpredicted cryptic reactivities were seen to 
CEF-10 and CEF-24 that were originally described as A3- 
and B18-restricted, respectively.
Test results summarized for the 42 donors
In all 42 donors, a total of 241 CEF peptide responses 
were predicted based on each donor’s HLA type. In 122 
instances, (51 %) responses were detected, and in 119 
instances (49 %) no response was detected (Fig. 5a). Thus, 
in approximately half of the cases the prediction was accu-
rate, and in the other half it was not. However, within the 
predicted responses that actually scored positive, about 
one-third (45 of 122, 37 %) were weak to borderline posi-
tive, that is cryptic. In only 15 % of the predicted cases was 
the actual recognition of the peptide dominant (36 of 241), 
and in 17 % it was subdominant.
Fifty-seven unpredicted responses were seen versus the 
122 predicted responses. Thus, of all the 179 responses 
detected, 68 % were predicted and 32 % were not. Within 
the unpredicted responses 20 (35 %) were dominant, 20 
(35 %) were subdominant, and 17 (30 %) were cryptic 
(Fig. 5b). Thus, 70 % of the non-predicted responses were 
prevalent, that is dominant or subdominant. These non-pre-
dicted responses are likely to contribute to host defense to 
an equal extent as the predicted ones, and one would miss 
them focusing only on predicted responses.
Weak or negative response to a single predicted peptide 
can misrepresent immunity to the antigen
In several PBMC donors, CD8 cells did not target pep-
tides that were predicted to be immune dominant. Is this 
because those donors did not develop strong immunity to 
the antigen, or because the donor responds strongly to the 
antigen, but to different peptides of the antigen? From the 
immune diagnostic perspective, this is the most critical 
distinction. For example, CEF-7 has been described as the 
immune dominant peptide of HCMV in HLA A2-positive 
donors [20], yet four of the 42 HCMV antibody-positive 
donors tested above were found to be negative for CEF-
7. We therefore tested our donors for the recall response 
to HCMVpp, a peptide pool that consists of 138 15-mer 
peptides which cover the sequence of the HCMVpp65 
protein. While—based on peptide length—this peptide 
pool is advertised to primarily activate CD4 cells, cell sepa-
ration experiments using CD4 and CD8 cell depletion by 
magnetic beads showed that HCMVpp is prevalently rec-
ognized by CD8 cells (Fig. 6a). As shown in Fig. 6b, all 
four donors who have been identified as CEF-7 negative 
(highlighted) mounted a vigorous T cell response against 
HCMVpp. The magnitude of HCMVpp-reactive T cells 
in these CEF7-negative donors was comparable to those 
donors who mounted a strong CEF7 response (Fig. 6b). 
The frequencies of CEF-7 peptide-reactive T cells, there-
fore, did not reflect on the frequency of T cells that targeted 
other determinants of the virus. In the case of HCMV, rely-
ing on test results obtained with a single predicted peptide 
can provide false-negative immune diagnostic information. 
What about EBV and Influenza are single peptides repre-
sentative of the overall anti-viral response?
Several EBV peptides are contained within the CEF 
pool, namely CEF 5, 6, 11, 12, 14, 15, 16, 17, 21, 22, 
23, 27, 28, and 30. Taking a closer look at the individual 
donors, these EBV peptides seem to be recognized by 
CD8 cells in an apparently random (aleatory) manner. In 
Donor 12 (see Fig. 1), CD8 cells target EBV peptide 11 in 
a dominant fashion, but do not respond detectably to pre-
dicted EBV peptides 5, 6 and 12. In Donor 28 (see Fig. 2), 
EBV peptide 30 induces only a subdominant response and 
peptides 5 and 6 are cryptic, while peptides 11 and 12 are 
not targeted at all. This apparently aleatory pattern within 
the EBV recall response holds up for the remainder of the 
donors as well (data not shown), and it can also be seen for 
the Flu peptides CEF1, 2, 3, 4, 8, 9, 10, 13, 18, 20, 25, 26. 
These findings further confirm that it can be misleading to 
conclude the overall strength with which a donor responds 
to other determinants of the same antigen from the mag-
nitude of the CD8 cell response to a single peptide, and 
thus, about the clonal sizes of T cells available in the host 
to combat the antigen.
Conclusion
The data we obtained clearly show that predicted peptides 
are not necessarily immune dominant. In 51 % of the test 
cases, the predicted peptide did not induce a detectable 
recall response. When it did, it was one of several targeted 
determinants among which it was subdominant or cryp-
tic. Thus, reliance on one or a few peptides can miss the 
majority of the antigen-specific CD8 cells, strongly arguing 
for the use of peptide pools for immune monitoring. One 
would predict that the larger the peptide pool, the more 
comprehensive the assessment of clonal sizes to an anti-
gen is likely to be. In an ideal approach, nonamer peptides 
would be synthesized that walk the entire sequence of the 
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antigen amino acid by amino acid, providing every possible 
determinant that can be recognized. Since ELISPOT is a 
high-throughput suitable assay, the peptides could be tested 
individually as we did previously [8, 21–27], or with pep-
tides pooled per test condition.
Recently 384-well ELISOT plates have been introduced 
that permit to test one-third of the PBMC cell number per 
well compared to standard 96-well plates, resulting in a 
precisely proportional (one-third) reduction of the spot 
count per well over a wide range of PBMC numbers plated 
per well [28]. Thus, the 384-well approach lends itself to 
detecting dominant and subdominant peptide responses. 
Using the 384-well approach, as few as 30,000 PBMC 
per well can be tested in this way providing 30 data points 
with one million PBMC [28]. Thus, a typical blood draw of 
20 ml would suffice to test up to 600 individual peptides or 
peptide pools.
When pooling peptides it is important to know the num-
ber of peptides that can be pooled without interference in 
the test system. We addressed this question using the very 
same CEF peptides, by testing the responses elicited by 
the individual peptides as was done in this study versus 
the response elicited by the pool of these 32 peptides. The 
number of spot-forming units (SFU) elicited by the indi-
vidual peptides added up closely the SFU number elicited 
by the peptide pool [29]. Peptide interferences, therefore, 
seem to be minor with pools up to 32 peptides.
The data presented here draw attention to the need for 
“agnostic” testing of large peptide libraries rather than 
relying on immune monitoring with one or few predicted 
peptides.
The data presented here are based on analyzing anti-
viral immunity. The T cell response to viruses follows more 
basic rules than immune responses to tumors. Most viruses 
are foreign antigens that do not affect negative and posi-
tive selection of the pre-immune T cell repertoire. In the 
absence of repertoire selection, it is primarily the efficacy 
of antigen processing and presentation that defines whether 
or not a peptide will become immune dominant. In the case 
of autoantigens and tumor antigens, the impact of these 
self-proteins on shaping the T cell repertoire needs to be 
considered. For example, immunization of myelin basic 
protein (MBP)-deficient mice permits to study which deter-
minant of this antigen is immune dominant when MBP is 
a foreign antigen. Strikingly, this determinant is cryptic in 
normal mice, in which endogenous MBP has contributed 
to shaping the T cell repertoire [21]. By analogy, also for 
tumor antigens, those peptides that are predicted to be the 
best binders may not be immune dominant, but the oppo-
site; they may be the ones to which the T cell system can-
not respond because these peptides induced tolerance. 
Such considerations further complicate the observations 
presented here: if immune dominance cannot be reliably 
predicted for the relatively simple situation of the anti-viral 
T cell response, how could it be predicted for the more 
complex anti-tumor/autoimmune setting? The pragmatic 
conclusion to which this study leads, should apply even 
more for immune monitoring to cancer, however, instead of 
relying on select “dominant” peptides, one might be better 
served by using peptide pools of the antigen.
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